Open-Label Extension of other SZ1839 (Iressa) trials

Study identifier:1839IL/0026

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Multi-centre, Open-label Extension trial of treatment with ZD1839 (Iressa) in patients who have been treated in other ZD1839 Clinical Trials and may benefit from continued Monotherapy ZD 1839.

Medical condition

cancer

Phase

Phase 3

Healthy volunteers

Study drug

Gefitinib (Iressa)

Sex

All

Actual Enrollment

100

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Feb 2000

Primary Completion Date: -

Study Completion Date: 01 Oct 2003

Study design

Allocation: N/A
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Apr 2009 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions

Documents available

Trial Results Summaries
Available here

Contacts

Contact

null AstraZeneca Clinical Study Information

800-236-9933

Contact Backup

null AstraZeneca Information, (Outside US)

001-800-236-9933